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AJP	 52	(10.7)	 6	(11.5)	 15	(32.6)	 14	(30.4)	 17	(37.0)	 	 45	(86.5)	
AJRCCM	 51	(10.5)	 4	(7.8)	 7	(14.9)	 7	(14.9)	 28	(59.6)	 	 29	(60.4)	
AON	 37	(7.6)	 16	(43.2)	 5	(23.8)	 3	(14.3)	 8	(38.1)	 	 24	(72.7)	
Blood	 52	(10.7)	 0	(0.0)	 9	(17.3)	 4	(7.7)	 26	(50.0)	 	 23	(60.5)	
Gast.	 53	(10.9)	 1	(1.9)	 7	(13.4)	 7	(13.5)	 30	(57.7)	 	 30	(68.2)	
Hep.	 50	(10.3)	 7	(14.0)	 9	(20.9)	 4	(9.3)	 27	(62.8)	 	 21	(60.0)	
JACI	 51	(10.5)	 7	(13.7)	 12	(27.3)	 5	(11.4)	 25	(56.8)	 	 27	(64.3)	
JCO	 51	(10.5)	 0	(0.0)	 10	(19.6)	 4	(7.8)	 35	(68.6)	 	 28	(57.1)	
JACC		 50	(10.3)	 4	(8.0)	 16	(34.8)	 15	(32.6)	 34	(73.9)	 	 30	(66.7)	






















































































		Yes	 392	(80.7)	 31	(7.9)	 65	(18.0)	 42		(11.6)	 216	(59.8)	 218	
(64.7)	
		No	 94	(19.3)	 16	(17.0)	 34	(43.6)	 25	(32.1)	 33	(42.3)	 64	(72.7)	












0.82			Industry	 216	(44.4)	 11	(5.1)	 25	(12.2)	 18	(8.8)	 131	(63.9)	 117	
(65.7)	
		Non-industry	 270	(55.6)	 36	(13.3)	 74	(31.6)	 49	(20.9)	 118	(50.4)	 165	
(66.8)	












0.79			≥	1	US	site		 250	(51.4)	 15	(6.0)	 35	(14.9)	 23	(9.8)	 133	(56.6)	 148	
(65.8)	
		Non-US	 236	(48.6)	 32	(13.5)	 64	(31.4)	 44	(21.6)	 116	(56.9)	 134	
(67.0)	










0.01			Yes		 372	(76.5)	 23	(6.2)	 79	(22.6)	 56	(16.0)	 195	(55.9)	 231	
(64.0)	
		No	 114	(23.5)	 24	(21.1)	 20	(22.2)	 11	(12.2)	 54	(60)	 51	(79.7)	














		<	100	 206	(42.4)	 38	(18.5)	 41	(24.4)	 24	(14.3)	 87	(51.8)	 121	
(72.0)	
	
Notes:		
a	Trials	receiving	either	full	or	partial	industry	support	were	designated	as	having	received	industry	funding.	
b	Percentages	are	expressed	as	the	fraction	of	total	trials	in	each	row.	
c	Trials	registered	>	30	days	after	enrollment	start	were	considered	to	have	been	registered	retrospectively.	Note	that	ICMJE	policy	mandates	
registration	prior	to	enrollment	start.	
d	Among	439	registered	trials,	we	could	not	determine	timeliness	of	registration	for	2	(1	published	in	Gastroenterology	and	the	other	in	Journal	of	
Clinical	Oncology),	as	enrollment	start	date	was	missing	from	registrations.	We	excluded	these	2	trials	from	analyses	of	association	pertaining	to	overall	
timeliness	of	registration	and	timelines	of	registration	relative	to	initial	primary	outcome	ascertainment.	
e	Percentages	are	expressed	as	the	fraction	of	registered	trials	(total	-	unregistered)	in	each	row.	
f	Due	to	the	nature	of	the	primary	outcome	(i.e.	median	survival),	we	could	not	determine	if	retrospective	registration	occurred	after	initial	primary	
outcome	ascertainment	in	8	cases:	1	in	Blood;	1	in	Hepatology;	2	in	Journal	of	Allergy	and	Clinical	Immunology;	and	4	in	Journal	of	Clinical	Oncology.	
These	trials	were	excluded	from	analyses	of	association	pertaining	to	timeliness	of	registration	relative	to	initial	primary	outcome	ascertainment.	
g	Registered	and	published	primary	endpoints	were	considered	concordant	if	they	did	not	differ	in	any	of	the	following	3	domains:	number	of	outcomes,	
outcome	definition(s),	or	outcome	time	frame(s).	
h	Twenty-six	of	439	registered	trials	did	not	have	a	primary	outcome	designated	in	their	publication	and	were	therefore	excluded	from	analyses	of	
association	pertaining	to	primary	endpoint	concordance.			
i	Primary	endpoint	favorability	could	not	be	judged	for	61	trials.	These	trials	were	excluded	from	analyses	of	association	pertaining	to	primary	endpoint	
favorability.	
j	Percentages	are	expressed	as	the	fraction	of	trials	in	each	row	for	which	primary	endpoint	favorability	could	be	judged	(row	totals	not	shown)	
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Timeliness	of	Registration	
	 Among	the	439	registered	trials,	99	(23%)	were	registered	retrospectively	
(i.e.	at	least	30	days	after	beginning	patient	enrollment)	based	on	the	enrollment	
start	date	reported	in	the	registry.	The	median	delay	in	registration	was	8	months	
(IQR,	5-19;	range,	1-88).	Sixty-seven	(68%)	of	the	99	retrospectively	registered	
trials,	or	15%	of	all	439	registered	trials,	were	registered	late	enough	to	have	
potentially	permitted	premature	examination	of	trial	results	after	collection	of	the	
primary	outcome	among	participants	enrolled	at	inception	(Table	4).	Of	302	trials	
with	a	registered	primary	completion	date,	7	(2%)	were	registered	after	reported	
completion	of	data	collection	for	the	trial’s	primary	outcomes.	Two	(2%)	of	88	
retrospectively	registered	trials	that	listed	a	manuscript	submission	date	were	
found	to	have	registered	after	submission	of	the	manuscript	to	the	publishing	
journal.	Only	one	(1%)	of	99	retrospectively	registered	trials	acknowledged	late	
registration	in	its	publication,	attributing	the	delay	to	principal	investigator	
oversight	and	offering	access	to	the	original	study	protocol	upon	request.[34]	
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Table	4.	Illustrative	examples	of	prospective	trial	registration,	retrospective	trial	registration	occurring	without	possibility	for	informed	interim	
analyses,	and	retrospective	registration	occurring	with	possibility	for	interim	analyses.	
	
Reference	 Registration	
No.	
Registration	
Date	
Enrollment	
Start	
Registration	
Delay	
Registered	Primary	
Endpoint	(Time	Frame)	
Registration	Timing	
J	Am	Soc	Nephrol.	2010	
Jun;21(6):1052-61.	
NCT00426153	
	
1/22/2007	
	
1/31/2007	
	
N/A	 Percentage	change	in	liver	
volume	(12	months)	
Prospective	
J	Allergy	Clin	Immunol.	2015	
Mar;135(3):670-5.e3.	
	
NTR2205	
	
2/8/2010	
	
1/1/2010	
	
1	month	 Induced	sputum	neutrophil	
and	eosinophil	percentage	
counts	(9	weeks)	
	
Retrospective	
J	Allergy	Clin	Immunol.	2015	
Apr;135(4):922-29.e6.	
	
NCT02024659	
	
12/27/2013	
	
9/30/2010	
	
39	months	 Nasal	polyp	size	(2	weeks)	
	
Retrospective	(after	
initial	primary	
endpoint	
ascertainment)	
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	Journals	did	not	differ	significantly	in	their	rates	of	overall	timely	
registration	(p=0.21),	but	did	differ	in	their	rates	of	registration	before	initial	
primary	outcome	ascertainment	(p=0.004)	(Table	2).	Trials	involving	industry	
funding,	enrollment	sites	in	the	US,	and	assessing	drugs,	devices,	or	
vaccines/biological	each	had	higher	rates	of	prospective	registration	as	compared	to	
those	without	industry	funding,	enrolling	at	only	non-US	sites,	and	assessing	non-
regulated	interventions	(Table	3).		
Primary	Endpoint	Concordance	
	 Among	the	439	registered	trials,	15	(3.4%)	failed	to	register	a	primary	
outcome	at	initial	registration,	though	14	of	these	15	published	a	primary	endpoint.	
Twenty-six	trials,	nearly	all	of	which	(n=25;	96%)	registered	a	primary	endpoint	at	
initial	registration,	did	not	explicitly	name	a	primary	endpoint	in	their	publications.	
Of	413	registered	trials	designating	at	least	one	primary	outcome	in	their	
publications,	sixty	percent	(n=249)	published	primary	endpoints	fully	concordant	
with	those	specified	at	initial	registration.	Twenty-six	percent	(n=109)	published	
primary	endpoints	discrepant	from	those	initially	registered.	Seventy-eight	(72%)	
of	these	109	discrepancies	were	based	on	either	the	number	or	definition	of	
primary	endpoints,	whereas	31	(28%)	were	based	on	the	specified	time	frame	of	
primary	outcome	ascertainment.	The	remaining	13%	(55	of	413)	registered	initial	
primary	endpoints	that	were	too	poorly	specified	to	permit	comparison	with	
published	endpoints.	Among	the	346	trials	registered	first	on	ClinicalTrials.gov,	19	
(5%)	trials	listed	original	primary	outcome	measures	that	were	submitted	at	least	
	 25	
	
30	days	subsequent	to	the	reported	registration	date.	Seven	(37%)	of	these	19	
involved	trials	whose	registration	was	already	retrospective.		
	 Among	the	249	trials	reporting	discrepant	published	and	registered	primary	
endpoints,	80%	(n=198)	were	registered	prospectively;	20%	(51	of	249)	were	
retrospectively	registered.	Neither	overall	timely	registration	(p=0.31)	nor	
registration	prior	to	initial	primary	outcome	ascertainment	(p=0.29)	was	associated	
with	concordance	between	registered	and	published	primary	endpoints.	Even	so,	
just	1	of	7	trials	determined	to	have	been	registered	after	their	primary	completion	
date	published	outcomes	concordant	with	those	initially	registered,	despite	the	
significant	delay	in	registration.	
Favorability	of	Trial	Results	
	 Among	the	486	trials	in	our	sample,	425	(87%)	reported	primary	endpoint	
results	from	which	inferences	about	the	statistical	significance	of	reported	outcomes	
could	be	drawn;	61	trials	(13%)	were	non-inferential,	including	descriptive	or	
single-arm	studies	without	a	specified	comparator,	and	could	not	be	judged	
accordingly.	Sixty-six	percent	(n=282)	of	the	425	inferential	trials	reported	
favorable	primary	outcome	results.	Of	143	(34%)	trials	reporting	unfavorable	
primary	outcome	results,	most	(n=135;	94%)	reported	findings	that	were	not	
significant,	while	8	(6%)	reported	negative	results.	Unregistered	trials	were	more	
likely	to	report	favorable	results	(31	of	35;	89%)	than	were	registered	trials	(251	of	
390;	64%)	(p=0.004),	irrespective	of	registration	timing.	Favorable	results	
reporting	appeared	to	be	more	frequent	among	trials	potentially	vulnerable	to	
unaccounted	primary	endpoint	modifications	(73	of	96;	76%),	which	included	those	
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that	were	unregistered	and	those	registered	after	initial	primary	outcome	
ascertainment,	compared	to	those	registered	prior	to	initial	primary	outcome	
ascertainment	(206	of	321;	64%),	but	our	findings	did	not	reach	statistical	
significance	(p=0.03).	
	
DISCUSSION	
Our	study	of	clinical	trials	recently	published	in	ten	high-impact	specialty	
society	journals,	all	requiring	trial	registration,	found	that	10%	of	published	trials	
were	unregistered.	Moreover,	among	registered	trials,	nearly	one	quarter	were	
registered	retrospectively.	Of	these,	more	than	two-thirds,	or	15%	of	all	registered	
trials,	were	registered	late	enough	after	participant	enrollment	to	afford	
opportunity	for	unaccounted	protocol	modifications	based	on	potential	premature	
analyses	of	observed	primary	endpoint	data.	Irrespective	of	registration	timing,	
post-registration	modifications	to	primary	endpoints	were	frequent,	as	26%	of	trials	
published	primary	outcomes	that	differed	from	those	specified	at	initial	registration.	
Finally,	unregistered	trials	reported	favorable	results	at	a	higher	rate	than	trials	that	
had	registered.	The	publication	of	unregistered	trials	and	trials	registered	after	
initial	primary	outcome	ascertainment	raises	concerns	about	selective	reporting	
and	the	integrity	of	reported	endpoints,	as	these	trials	are	vulnerable	to	potential	
changes	obscured	from	public	record.		
	 Despite	policies	to	improve	registration	rates,[32,	35,	36]	publication	of	
unregistered	trials	persists.	Our	study	demonstrates	that	even	the	highest	impact	
journals	associated	with	US	professional	medical	societies	publish	unregistered	
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trials,	albeit	some	more	frequently	than	others.	Consistent	with	earlier	studies,[13-
19]	our	findings	suggest	that,	more	than	a	decade	since	implementation	of	policies	
designed	to	promote	universal	registration,	continued	efforts	are	needed	to	ensure	
that	all	trials	are	registered,	even	among	those	that	are	published.	Registration	was	
more	frequent	among	trials	assessing	FDA-regulated	interventions	as	compared	to	
trials	evaluating	non-regulated	interventions,	such	as	behavioral	and	procedural	
interventions,	as	prior	research	has	suggested.[16]	We	additionally	noted	higher	
registration	rates	among	larger	trials	and	those	receiving	industry	support.	As	each	
of	the	specialty	society	journals	we	assessed	requires	trial	registration,	our	results	
indicate	that	some	journals	do	not	consistently	adhere	to	their	own	registration	
policies.	Prior	work	indicates	that	journals	may	in	fact	relax	their	own	registration	
requirements	for	various	reasons,	including	reluctance	to	penalize	otherwise	sound	
research,	apprehension	about	losing	manuscripts	to	rival	journals,	and	
misconceptions	about	the	applicability	of	registration	policies.[26]	Regardless	of	the	
rationale,	publication	of	unregistered	trials	risks	dissemination	of	trials	lacking	
accountability	and	potentially	influenced	by	selective	reporting.	Our	study	and	prior	
work	examining	cardiovascular	clinical	trials	demonstrate	that	unregistered	trials	
more	frequently	report	favorable	findings,[37]	though	a	recent	study	examining	a	
large	sample	of	unselected	trials	found	only	a	marginal	association.[38]	
Nevertheless,	stricter	adherence	to	registration	policies	may	help	prevent	the	
publication	of	trials	that	are	selectively	reporting	results,	biasing	the	medical	
literature.		
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While	registering	trials	can	help	mitigate	selective	reporting,	registration	
must	occur	prospectively,	in	accordance	with	ICMJE	policy,	to	effectually	detect	and	
deter	biased	reporting.	Despite	the	importance	of	timely	registration,	nearly	one	in	
four	trials	in	our	sample	was	published	despite	having	been	registered	
retrospectively.	Furthermore,	the	majority	of	late	registrations	were	delayed	to	such	
a	degree	after	enrollment	of	the	trials’	first	participants	that	it	could	have	permitted	
investigators	the	opportunity	to	amend	primary	endpoints	after	conducting	interim	
analyses.	For	trials	registered	after	ascertainment	of	endpoints,	it	is	nearly	
impossible	to	ascertain	the	degree	to	which	published	reports	diverge	from	original	
protocol	given	the	potential	for	modifications	occurring	covertly	pre-registration.	
While	the	frequency	of	post-registration	endpoint	modifications	does	not	appear	to	
depend	on	the	timeliness	of	trial	registration,	we	cannot	comment	on	the	frequency	
and	effects	of	pre-registration	protocol	modifications	beyond	identifying	situations	
in	which	they	could	have	potentially	occurred.		
This	study’s	findings	are	consistent	with	prior	research	that	timely	
registration	is	more	frequent	among	certain	trial	types,	including	those	involving	
FDA-regulated	interventions	and	those	receiving	industry	support.[14,	21]	
Compared	with	existing	studies,[14,	21,	23]	however,	retrospective	registration	was	
overall	less	frequent	in	our	sample.	Notwithstanding	the	possibility	that	specialty	
society	journals	are	in	better	overall	adherence,	there	are	several	methodological	
explanations	for	this	observation,	including	utilization	of	each	trial’s	earliest	
registration	record,	which	is	not	always	reported	in	publications,	application	of	a	
30-day	grace	period	between	enrollment	initiation	and	registration,	and	our	
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conservative	treatment	of	month-based	reporting	of	enrollment	start	dates	to	
ensure	that	true	prospective	registrations	were	not	misclassified.	Only	one	prior	
study	has	assessed	timeliness	of	registration	as	it	relates	to	its	potential	effect	on	
reported	outcomes,	specifically	within	the	context	of	the	six	highest	impact	general	
medical	journals.[21]	While	late	registration	was	less	frequent	among	specialty	
society	journals	as	compared	to	the	general	medical	journals	assessed	in	the	prior	
study	(23%	v.	28%),	this	study	observed	a	higher	proportion	of	late	registrations	
that	potentially	permitted	an	opportunity	for	endpoint	modification	informed	by	
potential	interim	analyses	(15%	vs.	8%).		
Implications	of	Findings		
Because	journals	control	the	dissemination	of	research,	they	are	well	
positioned	to	help	ensure	the	integrity	of	published	material,	which	includes	
adequate	and	timely	registration	of	published	trials.[39]	Specialty	society	journals,	
in	particular,	bear	a	significant	responsibility	to	this	end,	as	they	publish	trials	that	
are	of	great	interest	and	potential	influence	to	their	targeted	clinical	readerships.	As	
part	of	the	peer-review	process,	journals	generally	require	the	disclosure	of	trial	
registration	information,	though	discrepancies	between	registered	and	reported	
material	do	not	appear	to	influence	the	decision	to	accept	or	reject	manuscripts,[40]	
suggesting	that	editors	may	not	scrutinize	or	may	choose	to	disregard	discrepancies.	
If	oversight	is	in	fact	the	driver,	greater	attention	paid	to	trial	registration	during	
editorial	review	may	reduce	the	rate	at	which	potentially	biased	trials	are	published,	
including	those	that	are	unregistered	or	retrospectively	registered.	
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However,	while	ICMJE	policy	advocates	barring	retrospectively	registered	
trials	from	publication,	it	acknowledges	that	editors	may	judge	for	themselves	the	
circumstances	surrounding	late	registration	and	its	potential	bearing	on	reported	
endpoints.[32]	Accordingly,	our	findings	may	instead	stem	from	editors	deliberately	
choosing	to	publish	non-compliant	trials,	which	they	may	do	for	reasons	suggested	
previously.[26]	A	survey	of	editors	from	journals	endorsing	ICMJE	guidelines	found	
that	two-thirds	would	consider	publication	of	retrospectively	registered	trials,	
though	just	13%	indicated	that	consideration	would	be	situation-dependent.[25]	
For	journal	editors	weighing	the	decision	to	publish	such	trials,	ascertaining	
whether	registration	was	sufficiently	delayed	to	have	potentially	biased	the	
reported	results	may	help	guide	decisions	regarding	appropriate	exceptions.	The	
significance	of	study	findings	should	be	carefully	evaluated	in	the	decision	to	accept	
or	reject	given	the	potential	for	bias	that	exists	among	unregistered	or	
retrospectively	registered	trials.	If	journals	elect	to	move	forward	with	publishing	
these	trials,	steps	should	be	taken	to	ensure	that	original	trial	protocols,	approved	
by	and	obtained	directly	from	institutional	review	boards,	are	made	publicly	
available.	Additionally,	as	ICMJE	policy	suggests,	publication	of	non-compliant	trials	
should	be	accompanied	by	published	statements	explaining	why	registration	did	not	
occur	or	was	delayed	and,	further,	why	journal	editors	nonetheless	judged	the	trial	
fit	for	publication.[32]	Just	one	retrospectively	registered	trial	in	our	sample	
addressed	its	delayed	registration,	offering	to	make	available	its	original	protocol	
upon	request.	While	routine	posting	of	original	protocols	for	all	trials,	regardless	of	
registration	compliance,	may	mitigate	concerns	regarding	biased	reporting,	such	
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practices	are	infrequent.[41]	Among	journals	in	our	sample,	only	the	Journal	of	
Clinical	Oncology	requires	submission	and	publication	of	trial	protocols,	albeit	only	
for	phase	II	and	III	trials.[42]		
Limitations		
This	study	has	several	limitations.	First,	the	ICMJE	definition	of	a	clinical	trial	
is	subject	to	interpretation,	particularly	in	terms	of	what	constitutes	a	“health-
related	intervention”	and	a	“health	outcome”.	ICMJE	adopted	an	expanded	clinical	
trial	definition	in	2007	clarifying	the	scope	of	these	terms.[43]	Nevertheless,	
confusion	regarding	the	applicability	of	registration	requirements	for	interventional	
clinical	studies	may	exist	among	investigators	and	journals	editors.	While	ICMJE	
believes	that	investigators	should	err	towards	prospectively	registering	all	
interventional	studies	of	human	subjects	in	cases	of	uncertainty,[43]	subjectivity	in	
classifying	studies	as	“clinical	trials”	may	have	influenced	our	observed	frequency	of	
unregistered	trials,	particularly	in	cases	where	the	applicability	of	the	ICMJE	
definition	may	not	be	patent.	Second,	this	analysis	does	not	represent	a	perfect	audit	
of	ICMJE	registration	policy,	given	its	concession	of	a	30-day	grace	period	and	
exclusion	of	Phase	I	studies.	Nevertheless,	this	study	aimed	to	capture	the	spirit	of	
the	policy	rather	than	the	strict	letter	of	the	law	to	account	for	potential	flexibility	
on	the	part	of	journals	in	the	case	of	minimally	delayed	registrations.	Third,	our	
sample	by	design	comprised	a	group	of	clinical	trials	recently	published	in	select	
high-impact	specialty	society	journals;	accordingly,	our	findings	may	not	be	
representative	of	overall	trial	registration	patterns	or	of	all	specialty	society	
journals.	Nevertheless,	this	study	selected	the	highest-impact	specialty	journals,	the	
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most	prestigious	in	their	respective	fields,	which	are	expected	to	adhere	to	the	
highest	standards	of	trial	registration	practices.	Fourth,	our	cross-sectional	analysis	
did	not	examine	potential	improvements	in	trial	registration	within	journals	over	
time	nor	account	for	the	fact	that	journals	may	have	adopted	the	ICMJE’s	
registration	policy	at	different	time	points	since	its	implementation.	Even	so,	the	
earliest	trials	in	our	sample	were	published	in	January	2010,	nearly	half	a	decade	
since	the	policy	went	into	effect,	with	89%	of	sampled	trials	being	published	in	a	
three-year	span	since	2013.	Finally,	our	study	only	assessed	frequency	of	
modifications	to	primary	endpoints,	though	selective	reporting	may	manifest	
through	post-registration	protocol	modifications	to	other	elements	of	trial	design,	
including	secondary	endpoints	and	sample	size,	which	were	not	examined.	
Moreover,	this	study	is	only	able	to	comment	on	the	possibility	of	retrospective	
registration	to	invite	unaccounted	interim	analyses	or	pre-registration	protocol	
modifications	and	not	on	whether	such	analyses	or	modifications	actually	occurred.	
Such	information	could	only	be	ascertained	through	examination	of	original	trial	
protocols,	which	are	often	unavailable	and	lack	complete	information.[41]	
Additionally,	how	informative	interim	analyses	are,	in	some	cases,	depends	on	the	
trial’s	experience	of	participant	accrual,	details	of	which	are	also	generally	not	
readily	accessible.	
Conclusions	
Our	large	study	of	clinical	trials	published	in	ten	high	impact	specialty	society	
journals	demonstrates	that	registration	of	trials	continues	to	fall	short	of	the	ICMJE’s	
standards	necessary	to	ensure	a	complete	and	unbiased	evidence	base.	Ten	percent	
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of	published	trials	were	unregistered.	Moreover,	nearly	a	quarter	of	registered	trials	
were	registered	late,	the	majority	of	these	late	enough	to	afford	investigators	the	
chance	to	implement	modifications	potentially	informed	by	collected	data.	
Unregistered	trials	reported	favorable	study	findings	at	a	higher	rate	than	
registered	trials,	raising	concerns	that	lack	of	accountability	may	exert	undue	
influence	on	reported	results.	While	journals	should	generally	avoid	publishing	
improperly	registered	trials,	exceptions	should	be	acknowledged,	justified,	and	
furthermore	accompanied	by	an	evaluation	and	public	posting	of	the	study’s	original	
protocol.	Greater	adherence	to	the	ICMJE’s	prospective	trial	registration	policy	may	
help	reduce	the	publication	of	studies	failing	to	meet	proper	standards	and	improve	
the	integrity	of	published	trial	results.				
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